Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
et al., Cureus,
PSM multivariable analysis of the Itajaí trial showing significantly lower mortality with regular use of ivermectin prophylaxis. Immortal time bias
may significantly affect these results.
risk of death, 92.0% lower, RR 0.08, p < 0.001, treatment 2 of 283 (0.7%), control 15 of 283 (5.3%), NNT 22, adjusted per study, strictly regular use vs. non-use, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kerr et al., 6 Feb 2022, retrospective, propensity score matching, multivariable, Brazil, peer-reviewed, 9 authors, study period 7 July, 2020 - 2 December, 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.